Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abused and therapeutic drugs in animal treatment. In 2009, it became a vendor of the Chinese government and has been engaged in researching China-specific food safety and plant health issues.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NEOG | NEOGEN CORP | 2025-10-16 18:58:38 | 6 | 0.07 | 1.18 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEOG | 0000711377 | NEOGEN CORP | US6404911066 | 549300HJT9FC36N4UW43 | 382367843 | Nasdaq | 2835 | In Vitro & In Vivo Diagnostic Substances | 0531 | MI | 620 LESHER PLACE | LANSING | MI | 48912 | UNITED STATES | US | 5173729200 | 620 LESHER PLACE, LANSING, MI, 48912 | 620 LESHER PLACE, LANSING, MI, 48912 | — | Genomics | 1982 | Mike Nassif | 2,108 | http://neogen.com | 2,716,620,906 | 217,298,626 | 217,298,626 | Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abused and therapeutic drugs in animal treatment. In 2009, it became a vendor of the Chinese government and has been engaged in researching China-specific food safety and plant health issues. | 2025-10-10 21:06:24 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 2,716,620,906 | -537,993,691 | -16.5302 | 217,205,186 | 510,700 | 0.2357 |
| 2024 | 3,254,614,597 | -317,658,774 | -8.8923 | 216,694,486 | 385,574 | 0.1783 |
| 2023 | 3,572,273,371 | -752,470,193 | -17.3992 | 216,308,912 | 108,471,182 | 100.5874 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| David H. Naemura | Chief Financial Officer, Chief Operating Officer | 2025 | 571,500 | — | 836,400 | 0 | 17,681 | 2,680,181 |
| Douglas E. Jones | Chief Operating Officer | 2025 | 464,322 | — | 720,000 | 0 | 12,139 | 2,276,461 |
| John E. Adent | Chief Executive Officer, President | 2025 | 810,000 | — | 1,800,000 | 0 | 14,891 | 6,824,891 |
| John E. Adent | Chief Executive Officer, President | 2024 | 803,077 | — | 1,800,000 | 405,000 | 13,275 | 7,221,352 |
| Douglas E. Jones | Chief Operating Officer | 2024 | 522,035 | — | 720,000 | 154,440 | 22,030 | 2,498,505 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 2,974 |
| 2024 | 2,917 |
| 2023 | 2,640 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 894,661,000 | 924,222,000 | 822,447,000 |
| Cost Of Revenue | 473,285,000 | 460,322,000 | 416,492,000 |
| Gross Profit | 421,376,000 | 463,900,000 | 405,955,000 |
| Research And Development Expenses | 21,087,000 | 22,476,000 | 26,039,000 |
| General And Administrative Expenses | 218,167,000 | 199,889,000 | 201,179,000 |
| Operating Expenses | 1,482,373,000 | 405,237,000 | 368,440,000 |
| Operating Income | -1,060,997,000 | 58,663,000 | 37,515,000 |
| Net Income | -1,092,044,000 | -9,421,000 | -22,870,000 |
| Earnings Per Share Basic | -5.03 | -0.04 | -0.12 |
| Earnings Per Share Diluted | -5.03 | -0.04 | -0.12 |
| Weighted Average Shares Outstanding Basic | 216,894,861 | 216,481,878 | 188,881,000 |
| Weighted Average Shares Outstanding Diluted | 216,894,861 | 216,481,878 | 188,881,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 129,004,000 | 170,611,000 | 163,240,000 |
| Marketable Securities Current | 0 | 325,000 | 82,329,000 |
| Accounts Receivable | 153,384,000 | 173,005,000 | 153,253,000 |
| Inventories | 190,859,000 | 189,267,000 | 133,812,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 576,937,000 | 589,233,000 | 585,931,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 339,131,000 | 277,104,000 | 198,749,000 |
| Other Assets Non Current | 35,229,000 | 20,426,000 | 15,220,000 |
| Total Assets Non Current | 2,866,899,000 | 3,959,600,000 | 3,968,501,000 |
| Total Assets | 3,443,836,000 | 4,548,833,000 | 4,554,432,000 |
| Accounts Payable | 79,605,000 | 83,061,000 | 76,669,000 |
| Deferred Revenue | 5,558,000 | 4,632,000 | 4,616,000 |
| Short Term Debt | 19,301,000 | 2,447,000 | 0 |
| Other Liabilities Current | 32,180,000 | 22,800,000 | 6,951,000 |
| Total Liabilities Current | 174,011,000 | 154,323,000 | 145,472,000 |
| Long Term Debt | 874,810,000 | 888,391,000 | 885,439,000 |
| Other Liabilities Non Current | 42,854,000 | 35,259,000 | 35,877,000 |
| Total Liabilities Non Current | 1,198,571,000 | 1,250,368,000 | 1,274,743,000 |
| Total Liabilities | 1,372,582,000 | 1,404,691,000 | 1,420,215,000 |
| Common Stock | 34,728,000 | 34,658,000 | 34,599,000 |
| Retained Earnings | -536,424,000 | 555,620,000 | 565,041,000 |
| Accumulated Other Comprehensive Income | -28,898,000 | -30,021,000 | -33,251,000 |
| Total Shareholders Equity | 2,071,254,000 | 3,144,142,000 | 3,134,217,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 119,483,000 | 116,717,000 | 88,377,000 |
| Share Based Compensation Expense | 17,291,000 | 13,768,000 | 10,177,000 |
| Other Non Cash Income Expense | 2,839,000 | -4,829,000 | 486,000 |
| Change In Accounts Receivable | -11,638,000 | 20,101,000 | 53,879,000 |
| Change In Inventories | 16,117,000 | 55,949,000 | -9,955,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -402,000 | 13,751,000 | 18,642,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 58,244,000 | 35,264,000 | 41,028,000 |
| Purchases Of Marketable Securities | 0 | 0 | 12,523,000 |
| Sales Of Marketable Securities | 325,000 | 82,004,000 | 266,772,000 |
| Acquisition Of Property Plant And Equipment | 104,595,000 | 111,421,000 | 65,757,000 |
| Acquisition Of Business | 0 | 0 | -11,721,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -99,195,000 | -29,309,000 | 201,039,000 |
| Tax Withholding For Share Based Compensation | 1,500,000 | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 450,000,000 | — | — |
| Repayment Of Long Term Debt | 550,000,000 | 0 | 100,000,000 |
| Other Financing Activities | 2,242,000 | 2,456,000 | 1,195,000 |
| Cash From Financing Activities | -1,598,000 | 1,918,000 | -118,081,000 |
| Change In Cash | -41,607,000 | 7,371,000 | 118,767,000 |
| Cash At End Of Period | 129,004,000 | 170,611,000 | 163,240,000 |
| Income Taxes Paid | 26,544,000 | 22,303,000 | 15,473,000 |
| Interest Paid | 68,142,000 | 73,168,000 | 42,616,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -5.03 | -0.04 | -0.12 |
| Price To Earnings Ratio | -1.165 | -328.75 | -145.75 |
| Earnings Growth Rate | 12,475 | -66.6667 | -126.6667 |
| Price Earnings To Growth Ratio | -0.0001 | 4.9313 | 1.1507 |
| Book Value Per Share | 9.5496 | 14.5238 | 16.5936 |
| Price To Book Ratio | 0.6136 | 0.9054 | 1.054 |
| Ebitda | -907,898,000 | 171,751,000 | 108,234,000 |
| Enterprise Value | 2,036,110,885.46 | 3,566,963,695.7 | 4,025,727,690 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.4317 | 0.2833 | 0.2825 |
| Capital Expenditures | 181,510,000 | 195,072,000 | 176,542,000 |
| Free Cash Flow | -123,266,000 | -159,808,000 | -135,514,000 |
| Return On Equity | -0.5272 | -0.003 | -0.0073 |
| One Year Beta | -0.1493 | 1.3688 | 1.1459 |
| Three Year Beta | 0.6306 | 1.0547 | 1.0203 |
| Five Year Beta | 0.7493 | 1.0201 | 1.003 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| ADENT JOHN EDWARD | Former CEO | 2025-10-13 | 3,063 | A | 333,714 |
| ADENT JOHN EDWARD | Former CEO | 2025-10-13 | 865 | D | 332,849 |
| ADENT JOHN EDWARD | Former CEO | 2025-10-13 | 3,063 | D | 3,063 |
| Jones Douglas Edward | Former COO | 2025-10-13 | 783 | A | 89,241 |
| Jones Douglas Edward | Former COO | 2025-10-13 | 383 | D | 88,858 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Greg Gianforte | 2019-07-01 | MT00 | Purchase | 2019-06-12 | Joint | $100,001 - $250,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Carnegie Investment Counsel | 2025-09-30 | 126,762 | 22,200 | 5.71 |
| BEACON INVESTMENT ADVISORY SERVICES, INC. | 2025-09-30 | 98,943 | 17,328 | 5.71 |
| Blue Trust, Inc. | 2025-09-30 | 640 | 112 | 5.7143 |
| Avanza Fonder AB | 2025-09-30 | 93,844 | 16,435 | 5.71 |
| CWM, LLC | 2025-09-30 | 78,000 | 13,718 | 5.686 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Fund | CFSLX | 12,248 | 70,426 | 0.0147 |
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Select Fund | CFSSX | 70,594 | 405,915.5 | 0.0283 |
| Grandeur Peak Global Trust | 2025-07-31 | Investor Class | GPROX | 72,302 | 336,204.3 | 0.2681 |
| Grandeur Peak Global Trust | 2025-07-31 | Institutional Class | GPRIX | 72,302 | 336,204.3 | 0.2681 |
| Grandeur Peak Global Trust | 2025-07-31 | Institutional Class | GPGEX | 3,794 | 17,642.1 | 0.1431 |